Evidence map›Paper›PMID 36508123›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2023

Tumor P70S6K hyperactivation is inversely associated with tumor-infiltrating lymphocytes in triple-negative breast cancer.

Rebeca Jimeno, Silvana Mouron, Roberto Salgado, Sherene Loi, Belén Pérez-Mies, Rodrigo Sánchez-Bayona, Luis Manso, Mario Martínez, Ana Garrido-García, Rosario Serrano-Pardo and 2 more

Open access · hybridFull text read
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 3 countries.

Rebeca JimenoBreast Cancer Clinical Research Unit, Clinical Research Program, CNIO, Madrid, Spain.
Silvana MouronBreast Cancer Clinical Research Unit, Clinical Research Program, CNIO, Madrid, Spain.
Roberto SalgadoPeter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Sherene LoiPeter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Belén Pérez-MiesDepartment of Pathology, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRyCIS), Madrid, Spain.
Rodrigo Sánchez-BayonaDepartment of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.
Luis MansoDepartment of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.
Mario MartínezDepartment of Pathology, Hospital Universitario 12 de Octubre, Madrid, Spain.
Ana Garrido-GarcíaDepartment of Medical Oncology, Hospital Universitario La Princesa, Madrid, Spain.
Rosario Serrano-PardoDepartment of Pathology, Hospital Universitario La Princesa, Madrid, Spain.
Ramón ColomerDepartment of Medical Oncology, Hospital Universitario La Princesa, Madrid, Spain.
Miguel Quintela-FandinoBreast Cancer Clinical Research Unit, Clinical Research Program, CNIO, Madrid, Spain. mquintela@cnio.es.ORCID http://orcid.org/0000-0003-1648-1964
Hospital Universitario 12 De Octubre · ESHospital Universitario de La Princesa · ESPeter MacCallum Cancer Centre · AUSpanish National Cancer Research Centre · ESThe University of Melbourne · AUUniversidad de Alcalá · ES

Funding

CNIO Eva Plaza/CNIO Friends FellowshipERDF B2017/BMD3733Horizon 2020 893597Instituto de Salud Carlos III PI17/01865Instituto de Salud Carlos III PI19/00454Instituto de Salud Carlos III PI20/01458NIMHD NIH HHS L60 MD003733
6 · The paper itself

Abstract

purposeTriple-negative breast cancer (TNBC) is characterized by large heterogeneity and relative lack of available targeted therapies. To find therapeutic strategies for distinct patients with TNBC, several approaches have been used for TNBC clustering, including recently immune and phosphoproteomic patterns. Based on 70-kDa ribosomal protein S6 kinase (P70S6K)-TNBC clustering, the current study explores the immune profiling in TNBC tumors.

methodsStromal tumor-infiltrating lymphocytes (sTILs) were evaluated in human TNBC tumor samples. Furthermore, immunohistochemistry staining for CD8, CD4, Foxp3, and CD20 was performed in tissue microarrays (TMA) sections.

resultsHistological analysis showed decreased sTILs, CD20

conclusionsTIL infiltration and lymphocyte profiling vary in the context of hyperactivation of P70S6K in TNBC tumors.

Indexed as

Lymphocytes, Tumor-InfiltratingTriple Negative Breast NeoplasmsBiomarkers, TumorForkhead Transcription FactorsHumansPrognosisRibosomal Protein S6 Kinases, 70-kDaBiomarkers, TumorForkhead Transcription FactorsRibosomal Protein S6 Kinases, 70-kDaB cellsP70S6KT cellsTILTNBC

Identifiers

PMID36508123
PMCPMC10025236
OpenAlexW4311203635

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read102
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.